A Phase II, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study of Belimumab in Patients With Active Systemic Lupus Erythematosus

OBJECTIVE: To assess the safety, tolerability, biological activity, and efficacy of belimumab in combination with standard of care therapy (SOC) in patients with active systemic lupus erythematosus (SLE). METHODS: Patients with SELENA-SLEDAI score≥4 (N=449) were randomly assigned to belimumab (1, 4,...

Full beskrivning

Sparad:
Bibliografiska uppgifter
Huvudupphovsmän: Wallace, Daniel J., Stohl, William, Furie, Richard A., Lisse, Jeffrey R., McKay, James D., Merrill, Joan T., Petri, Michelle A., Ginzler, Ellen M., Chatham, W. Winn, McCune, W. Joseph, Fernandez, Vivian, Chevrier, Marc R., Zhong, John, Freimuth, William W.
Materialtyp: Artigo
Språk:Inglês
Publicerad: 2009
Ämnen:
Article
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC2758229/
https://ncbi.nlm.nih.gov/pubmed/19714604
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/art.24699
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk